Because of the high prevalence of RET gene mutation in advanced MTC, the low prevalence of grades 3 and 4 adverse events [39, 41] according to CTCAE [60], and the good preservation of the quality of life, highly selective RET inhibitor drugs have been more frequently tested in a neoadjuvant setting. Here, RET is linked to medullary thyroid gland carcinoma.